Intended for healthcare professionals

Letters “Breakthrough” drug in Alzheimer’s disease

Recent trial shows that solanezumab has disease modifying effects

BMJ 2015; 351 doi: (Published 28 August 2015) Cite this as: BMJ 2015;351:h4528
  1. Eric Karran, director of research1
  1. 1Alzheimer’s Research UK, Cambridge CB21 6AD, UK
  1. k.marais{at}

McCartney raises important points about the media reporting of solanezumab but does not fully explore the data’s real importance.1

Current drugs for Alzheimer’s disease treat the symptoms only.2 Disease modifying drugs could reduce the numbers of people living with severe stage Alzheimer’s.3

The extension study (EXPEDITION-EXT) was designed to …

View Full Text

Log in

Log in through your institution


* For online subscription